Recruiting
PHASE3
INTERVENTIONAL
NCT06937086
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
The main purpose of this study is to show whether in these individuals, treatment with both mirikizumab and tirzepatide, compared with treatment with mirikizumab and placebo, leads to decrease or disappearance of UC symptoms, and loss of at least one-tenth of the overall body weight. Participation in this study will last up to 61 weeks, including 52 weeks of treatment.
Interventions
Name:
Mirikizumab
Type:
DRUG
Description:
Administered IV
Name:
Mirikizumab
Type:
DRUG
Description:
Administered SC
Name:
Tirzepatide
Type:
DRUG
Description:
Administered SC
Name:
Placebo
Type:
DRUG
Description:
Administered SC
Primary Outcomes
Measure:
Percentage of Participants Who Simultaneously Achieve Clinical Remission and at Least 10% Weight Reduction
TimeFrame:
Week 52
Description:
Percentage of participants who simultaneously achieve clinical remission and at least 10% weight reduction.
Trial Information
NCT ID
NCT06937086
Status
Recruiting
Study Type
INTERVENTIONAL
Phases
PHASE3
Sponsor
Eli Lilly and Company
Last Updated
December 15, 2025